Quantitative pretreatment VOI analysis of liver metastases 99m Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT;Prätherapeutische quantitative VOI-analyse von lebermetastasen korrelation zwischen 99mTc-MAA SPECT/CT und FDG PET/CT und Ansprechen auf eine Behandlung mit SIRT

NuklearMedizin

Volumn 52, Issue 1, 2013, Pages 21-27

  Van de Wiele, C ^a   Stellamans, K ^b   Brugman, E ^b   Mees, G ^a   De Spiegeleer, B ^c   D'Asseler, Y ^a   Beels, L ^b   Maes, A ^b,d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Radiotherapy ^*  (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

SIRT VOI analysis treatment response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MACROSALB TC 99M; MICROSPHERE; YTTRIUM 90; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; RECEIVER OPERATING CHARACTERISTIC; SELECTIVE INTERNAL RADIATION THERAPY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84873953332     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0514-12-07     Document Type: Article

References (22)

1. Allal AS, Slosman DO, Kebdani T et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Biol Oncol Biol Phys 2004; 5: 1295-1300.
2. Aronen HJ, Pardo FS, Kennedy DN et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189-2200.
3. 99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT). BMC Nuclear Medicine 2005; 5: 1-10.
4. Flamen P, Vanderlinden B, Delatte P et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labelled resin microspheres. Phys Med Biol 2008; 53: 6591-6603.
5. Fukuda K, Taniguchi H, Hoh T et al. Relationship between oxygen and glucose metabolism in human liver tumours: positron emission tomography using 15O and 18F-deoxyglucose. Nucl Med Commun 2004; 25: 577-583.
6. 99mTc-macroaggregated albumin SPECT/ CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012: 53: 255-263.
7. Garin E, Rolland Y, Boucher E et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (Therasphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 2010; 37: 453-461.
8. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53: 371-377.
9. Hermans R, Meijerink M, van den Bogaert W et al. Tumor perfusion rate determined non-invasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-1356.
10. 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30: 571-592.
11. Mankoff DA, Dunnwald LK, Gralow Jr et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43: 500-509.
12. Mertens J, Dobbeleir A, Ham H et al. Standardized adedd metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging 2012; DOI 10.1007/s00259-012-2166-0
13. Miles KA, Griffiths MR, Keith CJ. Blood flowmetabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 22-28.
14. Miles KA, William RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008; 8: 81-86.
15. Miles KA, Williams RE, Yu D, Griffiths MR. Demonstrating intertumoural differences in vascularmetabolic phenotype with dynamic contrast-enhanced CT-PET. Int J Molecular Imaging 2011; 2011: 1-8.
16. Salem R, Lewandowski RJ, Sato KT et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10: 12-29.
17. Stewart EE, Chen X, Hadway J, Lee TY. Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model. Radiology 2006; 239: 740-750.
18. Van de Wiele C, Defreyne L, Peeters M, Lambert B. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q J Nucl Med Mol Imaging 2009; 53: 317-324.
19. Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary lo colorectal adenocarcinoma. JRBOP 2006; 66: S62-S73.
20. Williams J, Zhang Y, Russell J et al. Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status. Acta Oncol 2007; 46: 628-638.
21. Williams J, Zhang Y, Zhou H et al. Overview of radiosensitivity of human tumor cells to low-doserate irradiation. IJRBOP 2008; 72: 909-917.
22. Wong CY, Savin M, Sherpa KM et al. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy refractory metastatic liver carcinoma. Cancer Biother Radiopharm 2006; 21: 305-313.